Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 06 2022
Historique:
received: 14 01 2022
revised: 29 03 2022
accepted: 02 04 2022
pubmed: 18 4 2022
medline: 18 5 2022
entrez: 17 4 2022
Statut: ppublish

Résumé

People with opioid use disorder (OUD) experience lower quality of life (QoL) than the general population, but buprenorphine treatment for OUD could help improve QoL of individuals with OUD. Thus, we conducted a systematic review and meta-analysis of the impact of buprenorphine on QoL among people with OUD. Seven databases were searched through August 2020. We included English-language studies with pre- and post- QoL assessments internationally. Standardized mean differences were calculated for five domains of QoL measures using a random effects model for correlated effect sizes with robust variance estimation. Meta-regression was used to assess variation in effect sizes based on QoL domain, treatment, and patient factors. Twenty-one peer-reviewed studies from twelve countries were included. Only three studies included a no-treatment control group and five studies assigned groups using randomization. Improvements between baseline and follow-up were observed across all five domains of QoL measures (overall, physical, psychological, social, and environmental). The certainty of evidence was low for all domains of QoL, and very low for environmental QoL. We did not observe differences in the effect of buprenorphine on QoL by QoL domain, duration, dose, participant characteristics, or adjunctive counseling services. Buprenorphine treatment likely improves overall, physical, psychological, and social QoL, and may improve environmental QoL, for individuals with OUD. Findings are limited by study quality, including lack of control groups and incomplete reporting. Future studies with more rigorous methods and comprehensive reporting are needed.

Sections du résumé

BACKGROUND
People with opioid use disorder (OUD) experience lower quality of life (QoL) than the general population, but buprenorphine treatment for OUD could help improve QoL of individuals with OUD. Thus, we conducted a systematic review and meta-analysis of the impact of buprenorphine on QoL among people with OUD.
METHODS
Seven databases were searched through August 2020. We included English-language studies with pre- and post- QoL assessments internationally. Standardized mean differences were calculated for five domains of QoL measures using a random effects model for correlated effect sizes with robust variance estimation. Meta-regression was used to assess variation in effect sizes based on QoL domain, treatment, and patient factors.
RESULTS
Twenty-one peer-reviewed studies from twelve countries were included. Only three studies included a no-treatment control group and five studies assigned groups using randomization. Improvements between baseline and follow-up were observed across all five domains of QoL measures (overall, physical, psychological, social, and environmental). The certainty of evidence was low for all domains of QoL, and very low for environmental QoL. We did not observe differences in the effect of buprenorphine on QoL by QoL domain, duration, dose, participant characteristics, or adjunctive counseling services.
CONCLUSIONS
Buprenorphine treatment likely improves overall, physical, psychological, and social QoL, and may improve environmental QoL, for individuals with OUD. Findings are limited by study quality, including lack of control groups and incomplete reporting. Future studies with more rigorous methods and comprehensive reporting are needed.

Identifiants

pubmed: 35430522
pii: S0376-8716(22)00182-X
doi: 10.1016/j.drugalcdep.2022.109445
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Buprenorphine 40D3SCR4GZ

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

109445

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Olivia K Golan (OK)

School of Public Health, Georgia State University, Atlanta, GA, United States. Electronic address: orandallkosich1@gsu.edu.

Rachel Totaram (R)

School of Health Management & Informatics, University of Central Florida, Orlando, FL, United States.

Elizabeth Perry (E)

School of Public Health, Georgia State University, Atlanta, GA, United States.

Kennicia Fortson (K)

School of Public Health, Georgia State University, Atlanta, GA, United States.

Raul Rivera-Atilano (R)

School of Education, Florida Southern College, Lakeland, FL, United States.

Rebecca Entress (R)

School of Public Administration, University of Central Florida, Orlando, FL, United States.

Matthew Golan (M)

School of Law, Emory University, Atlanta, GA, United States.

Barbara Andraka-Christou (B)

School of Health Management & Informatics, University of Central Florida, Orlando, FL, United States; Department of Internal Medicine, University of Central Florida, Orlando, FL, United States.

Daniel Whitaker (D)

School of Public Health, Georgia State University, Atlanta, GA, United States.

Therese Pigott (T)

School of Public Health, Georgia State University, Atlanta, GA, United States; College of Education & Human Development, Georgia State University, Atlanta, GA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH